Delivery Order SPE2DB22D9367-SPE2DB25FSZ92
- Not listed
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on August 4, 2025, for the supply of Xtandi 80 mg tablets (60-unit quantity). The contract, which carries no set-aside designation, is scheduled for completion by August 5, 2025, and will be performed at the vendor's facility in Park Ridge, Illinois. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DLA's ongoing procurement of...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). The award, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, utilizes a firm fixed-price contract type with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on May 30, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award, effective through June 2, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its Park Ridge location. The company has been registered in the System for Award...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 tablets of Xtandi 40 mg. This delivery order was issued under a firm fixed-price contract type with an ultimate completion date of August 11, 2025, and no set-aside designation was used in the award. Xtandi is a prescription oncology medication used to treat prostate cancer, representing the...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 120 tablets of Xtandi 40 mg on September 12, 2025, with an ultimate completion date of September 15, 2025. This award was made without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery from its location in Park Ridge, IL 60068. Xtandi is an oral pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract, which carries no set-aside designation, is scheduled for completion by July 22, 2025, with performance at the vendor's Park Ridge location. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The order, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, carries no set-aside designation. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, a prescription medication used in oncology treatment. The contract, awarded on August 29, 2025, with an ultimate completion date of September 2, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at the vendor's location in Park Ridge, Illinois. This delivery order is issued under DMS...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSZ92Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The award was issued on September 17, 2025, with an ultimate completion date of September 18, 2025, and carries no set-aside designation. Xtandi is an oncology medication used in the treatment of prostate cancer, reflecting the Defense Logistics Agency's continued procurement of specialized pharmaceutical products to support Department of Defense healthcare facilities. The contract was awarded without competition under the agency's existing indefinite delivery contract authority. This delivery order is issued under DMS Pharmaceutical Group's substantial single-award Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, valued at $499,999,999 and extending through November 2026. This indefinite delivery vehicle enables the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables supporting military health facilities nationwide. DMS Pharmaceutical Group's established presence as a federal pharmaceutical supplier, with contract awards dating to 2001 and a robust portfolio of oncology and specialty medication deliveries, positions the company as a critical distributor within the Department of Defense pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/17/25 |